The mission of the Biosafety Core is two-fold. First and foremost, the core provides a fully managed, equipped, and safe working environment for the study of HIV, Mycobacterium tuberculosis (MTB) and other infectious pathogens. Secondly, the core actively develops state-of-the-art molecular methodologies for assessment of host/pathogen interactions for translational applications, such as the development of real-time quantitative PCR methodologies for the study of HIV replication and diversity in research samples. In addition, the core personnel have assumed the responsibility for training all users in good laboratory practices, periodic retraining to assure compliance with laboratory regulations, and providing services to promote research by all investigators in the CWRU/UHC research community. Dedicated BL-3 and BL-2+ laboratories are located across from each other on the 10th floor of the Biomedical Research Building in the Division of Infectious Diseases. A five-member Biosafety Committee meets to supervise safety procedures, and a six-member Scientific Team meets to determine developmental direction by the core on a quarterly basis. The activities of this core are essential to the success of CFAR, as both safety in investigation of biohazardous pathogens and development of new methodologies to assess host/HIV interactions constitute key elements in the AIDS research efforts at CWRU/UHC. The unique aspects of the core (i.e., the ability to study the interaction between HIV and virulent Mycobacterium tuberculosis), underscores the importance of this core as a major research strength of the CWRU/UHC CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-15
Application #
7636805
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
15
Fiscal Year
2008
Total Cost
$218,287
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786

Showing the most recent 10 out of 539 publications